Published in J Transl Med on September 19, 2011
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med (2012) 1.47
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12
CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer (2013) 1.06
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother (2012) 0.98
Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol (2012) 0.87
Immune cell impact of three differently coated lipid nanocapsules: pluronic, chitosan and polyethylene glycol. Sci Rep (2016) 0.81
Impact of carbon nanotubes and graphene on immune cells. J Transl Med (2014) 0.81
Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care (Basel) (2016) 0.80
The immune-related role of BRAF in melanoma. Mol Oncol (2014) 0.78
Application of carbon nanotubes layered on silicon wafer for the detection of breast cancer marker carbohydrate antigen 15-3 by immuno-polymerase chain reaction. J Mater Sci Mater Med (2013) 0.76
Evaluation of SLOG/TCI-III pediatric system on target control infusion of propofol. J Transl Med (2011) 0.75
Preamble to the 2015 SITC immunotherapy biomarkers taskforce. J Immunother Cancer (2015) 0.75
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother (2005) 1.25
Providing web servers and training in Bioinformatics: 2010 update on the Bioinformatics Links Directory. Nucleic Acids Res (2010) 1.19
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res (2009) 3.83
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol (2003) 2.87
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res (2007) 2.69
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood (2009) 2.54
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol (2005) 2.51
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol (2006) 2.42
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother (2004) 2.42
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer (2006) 2.40
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res (2002) 1.89
Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol (2008) 1.89
Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res (2008) 1.85
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
What's next in translational medicine? Clin Sci (Lond) (2007) 1.85
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
The dual role of IL-10. Trends Immunol (2003) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol (2003) 1.72